NASDAQ:CTMX CytomX Therapeutics (CTMX) Stock Price, News & Analysis → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Free CTMX Stock Alerts $1.61 -0.02 (-1.23%) (As of 12:12 PM ET) Add Compare Share Share Today's Range$1.58▼$1.6450-Day Range$1.45▼$2.7452-Week Range$1.04▼$2.86Volume143,533 shsAverage Volume825,525 shsMarket Capitalization$109.05 millionP/E RatioN/ADividend YieldN/APrice Target$3.10 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get CytomX Therapeutics alerts: Email Address CytomX Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside92.2% Upside$3.10 Price TargetShort InterestBearish5.30% of Shares Sold ShortDividend StrengthN/ASustainability-0.74Upright™ Environmental ScoreNews Sentiment0.50Based on 8 Articles This WeekInsider TradingSelling Shares$73,200 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.21) to ($0.29) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.43 out of 5 starsMedical Sector141st out of 907 stocksPharmaceutical Preparations Industry50th out of 422 stocks 3.2 Analyst's Opinion Consensus RatingCytomX Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageCytomX Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.30% of the outstanding shares of CytomX Therapeutics have been sold short.Short Interest Ratio / Days to CoverCytomX Therapeutics has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in CytomX Therapeutics has recently increased by 8.13%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCytomX Therapeutics does not currently pay a dividend.Dividend GrowthCytomX Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCytomX Therapeutics has received a 74.21% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Preclinical research services for physical health", "Basic medical research services", and "Clinical research services for cancer" products. See details.Environmental SustainabilityThe Environmental Impact score for CytomX Therapeutics is -0.74. Previous Next 1.9 News and Social Media Coverage News SentimentCytomX Therapeutics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for CytomX Therapeutics this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 1 people have added CytomX Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CytomX Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $73,200.00 in company stock.Percentage Held by InsidersOnly 7.00% of the stock of CytomX Therapeutics is held by insiders.Percentage Held by Institutions67.77% of the stock of CytomX Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for CytomX Therapeutics are expected to decrease in the coming year, from ($0.21) to ($0.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CytomX Therapeutics is -80.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CytomX Therapeutics is -80.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchSee this before next week's Fed meetingSee this before next week's Fed Meeting Doc Eifrig just released a new video detailing "the perilous moment Americans are in right now." Angry voters, mounting government debt, and blood in the streets… But he's got a way out – a unique way to come out on top no matter who wins this presidential election. (Last time we shared this, it led to a 995% gain.) Click here to see it. About CytomX Therapeutics Stock (NASDAQ:CTMX)CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.Read More CTMX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CTMX Stock News HeadlinesApril 24, 2024 | americanbankingnews.comCytomX Therapeutics (NASDAQ:CTMX) Downgraded by StockNews.com to "Hold"April 23, 2024 | msn.comJP Morgan Upgrades CytomX Therapeutics (CTMX)April 25, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItSee this before next week's Fed Meeting Thousands of investing ideas come across his desk every year… But Doc Eifrig just revealed THIS ONE "will go down as one of the smartest and most lucrative financial moves of the decade." (Last time we shared this, it led to a 995% gain.)April 23, 2024 | americanbankingnews.comCytomX Therapeutics (NASDAQ:CTMX) Upgraded to "Neutral" at JPMorgan Chase & Co.April 22, 2024 | msn.comCytomX upgraded to Neutral at J.P MorganApril 18, 2024 | americanbankingnews.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Short Interest Down 5.9% in MarchApril 17, 2024 | finance.yahoo.comCytomX Therapeutics, Inc. (CTMX)April 8, 2024 | globenewswire.comCytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid TumorsApril 25, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItSee this before next week's Fed Meeting Thousands of investing ideas come across his desk every year… But Doc Eifrig just revealed THIS ONE "will go down as one of the smartest and most lucrative financial moves of the decade." (Last time we shared this, it led to a 995% gain.)April 3, 2024 | globenewswire.comCytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with AstellasMarch 23, 2024 | investing.comCytomX Therapeutics executive sells over $26k in company stockMarch 23, 2024 | investing.comCytomX Therapeutics executive sells shares worth over $6,000March 21, 2024 | globenewswire.comCytomX Therapeutics Appoints Dr. Zhen Su to Board of DirectorsMarch 18, 2024 | globenewswire.comCytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with AstellasMarch 13, 2024 | finance.yahoo.comCytomX Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS LagsMarch 12, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Legend Biotech (LEGN) and CytomX Therapeutics (CTMX)March 12, 2024 | markets.businessinsider.comJ.P. Morgan Keeps Their Sell Rating on CytomX Therapeutics (CTMX)March 12, 2024 | finance.yahoo.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Q4 2023 Earnings Call TranscriptMarch 12, 2024 | investorplace.comWhy Is CytomX Therapeutics (CTMX) Stock Down 18% Today?March 12, 2024 | benzinga.comWhy Oracle Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving PremarketMarch 11, 2024 | marketwatch.comStocks to Watch: Oracle, Mission Produce, CytomX TherapeuticsMarch 11, 2024 | marketwatch.comCytomX Therapeutics Shares Fall 19% After Bristol Myers Squibb Decides Not to Continue Developing CandidateMarch 11, 2024 | benzinga.comRecap: CytomX Therapeutics Q4 EarningsMarch 11, 2024 | globenewswire.comCytomX Therapeutics Reports 2023 Financial Results and Provides Business UpdateMarch 8, 2024 | benzinga.comCytomX Therapeutics's Earnings OutlookMarch 4, 2024 | globenewswire.comCytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024February 28, 2024 | ca.finance.yahoo.comBMY Oct 2024 45.000 putSee More Headlines Receive CTMX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CytomX Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/11/2024Today4/25/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CTMX CUSIPN/A CIK1501989 Webwww.cytomx.com Phone(605) 515-3185Fax650-351-0353Employees120Year FoundedN/APrice Target and Rating Average Stock Price Target$3.10 High Stock Price Target$3.19 Low Stock Price Target$3.00 Potential Upside/Downside+89.9%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-570,000.00 Net Margins-0.56% Pretax Margin3.28% Return on EquityN/A Return on Assets-0.26% Debt Debt-to-Equity RatioN/A Current Ratio1.17 Quick Ratio1.17 Sales & Book Value Annual Sales$101.21 million Price / Sales1.09 Cash FlowN/A Price / Cash FlowN/A Book Value($0.71) per share Price / Book-2.30Miscellaneous Outstanding Shares67,732,000Free Float62,991,000Market Cap$110.40 million OptionableOptionable Beta1.00 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Sean A. McCarthy DPHIL (Age 57)Chairman & CEO Comp: $1.03MKey CompetitorsSeres TherapeuticsNASDAQ:MCRBRezoluteNASDAQ:RZLTImmunicNASDAQ:IMUXSocietal CDMONASDAQ:SCTLCartesian TherapeuticsNASDAQ:RNACView All CompetitorsInsiders & InstitutionsCongress Park Capital LLCSold 5,500 shares on 4/16/2024Ownership: 0.345%Sean A MccarthySold 20,223 sharesTotal: $42,266.07 ($2.09/share)Lloyd A RowlandSold 5,268 sharesTotal: $11,010.12 ($2.09/share)Jeffrey B LandauSold 6,562 sharesTotal: $13,714.58 ($2.09/share)Christopher OgdenSold 2,971 sharesTotal: $6,209.39 ($2.09/share)View All Insider TransactionsView All Institutional Transactions CTMX Stock Analysis - Frequently Asked Questions Should I buy or sell CytomX Therapeutics stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CytomX Therapeutics in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" CTMX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CTMX, but not buy additional shares or sell existing shares. View CTMX analyst ratings or view top-rated stocks. What is CytomX Therapeutics' stock price target for 2024? 3 equities research analysts have issued twelve-month price objectives for CytomX Therapeutics' stock. Their CTMX share price targets range from $3.00 to $3.19. On average, they anticipate the company's stock price to reach $3.10 in the next twelve months. This suggests a possible upside of 92.2% from the stock's current price. View analysts price targets for CTMX or view top-rated stocks among Wall Street analysts. How have CTMX shares performed in 2024? CytomX Therapeutics' stock was trading at $1.55 at the start of the year. Since then, CTMX shares have increased by 3.9% and is now trading at $1.61. View the best growth stocks for 2024 here. Are investors shorting CytomX Therapeutics? CytomX Therapeutics saw a increase in short interest in April. As of April 15th, there was short interest totaling 3,590,000 shares, an increase of 8.1% from the March 31st total of 3,320,000 shares. Based on an average daily volume of 905,200 shares, the short-interest ratio is presently 4.0 days. View CytomX Therapeutics' Short Interest. When is CytomX Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our CTMX earnings forecast. How were CytomX Therapeutics' earnings last quarter? CytomX Therapeutics, Inc. (NASDAQ:CTMX) announced its earnings results on Monday, March, 11th. The biotechnology company reported $0.01 EPS for the quarter, missing the consensus estimate of $0.02 by $0.01. The biotechnology company had revenue of $26.61 million for the quarter, compared to the consensus estimate of $23.36 million. What ETF holds CytomX Therapeutics' stock? Formidable ETF holds 282,099 shares of CTMX stock, representing 1.88% of its portfolio. What is Sean A McCarthy's approval rating as CytomX Therapeutics' CEO? 12 employees have rated CytomX Therapeutics Chief Executive Officer Sean A McCarthy on Glassdoor.com. Sean A McCarthy has an approval rating of 65% among the company's employees. 80.0% of employees surveyed would recommend working at CytomX Therapeutics to a friend. What other stocks do shareholders of CytomX Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other CytomX Therapeutics investors own include Gilead Sciences (GILD), Exelixis (EXEL), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), SCYNEXIS (SCYX), Bausch Health Companies (BHC), Bristol-Myers Squibb (BMY) and Dynavax Technologies (DVAX). Who are CytomX Therapeutics' major shareholders? CytomX Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Congress Park Capital LLC (0.35%). Insiders that own company stock include Amy C Peterson, Carlos Campoy, Christopher Ogden, Elaine V Jones, Jeffrey B Landau, Lloyd A Rowland, Marcia Belvin and Sean A Mccarthy. View institutional ownership trends. How do I buy shares of CytomX Therapeutics? Shares of CTMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CTMX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street Star“The Biggest Bubble of All Time” – Here’s What to Do.Chaikin AnalyticsBetter than Bitcoin? The Biotech Stock with 46,751% PotentialBehind the MarketsGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchThese AI trades triggered this morning (545% return)Prosper Trading AcademyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytomX Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
